Scientists from Medistem laboratories, Inc. (MDSM) have published a peer reviewed paper outlining the practical rationale for a broader medical use of cord stem cells, without the limiting feature of immune suppression.
This concept for cord blood transplants, opens the door to an increasing number of potential medical applications, including Medistem’s Angiostem platform, now under development for U.S. commercialization.
Let us hear your thoughts below:
